Chronic Obstructive Pulmonary Disease – Landscape & Forecast – Disease Landscape & Forecast
The chronic obstructive pulmonary disease (COPD) therapy market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics will have a significant impact on this trend. Some generic LABA/ICS FDCs and LAMAs have already launched in the United States and Europe, and more will reach the market in the coming years. Although physicians will welcome additional treatment options for this chronic disease as a result of the development of novel drug classes, including biologics (e.g., IL-33, IL-13/IL-4, IL-5 inhibitors) and novel inhaled and nebulized therapies (e.g., PDE3/4 inhibitors), significant unmet need remains for therapies that can repair lung tissue or halt disease progression.
QUESTIONS ANSWERED
- Will LABA/LAMA FDCs continue to gain market share, or will generic therapies or branded LABA/LAMA/ICS FDCs threaten these agents?
- What are key opinion leaders’ insights on current treatment options (e.g., GSK’s Advair, Trelegy, Breo; GSK / Innoviva’s Anoro; Boehringer Ingelheim’s Spiriva, Stiolto / Spiolto; AstraZeneca’s Breztri, Symbicort)? What factors drive physicians’ treatment decisions?
- How will the market evolve over the 10-year forecast period?
- Which emerging therapies have the most potential for uptake? Will nebulized therapies be accepted? Will the use of IL-5 inhibitors be accepted for COPD? How will the launch of these and other biologics influence the COPD market?
- What is the unmet need in COPD treatment?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Chronic Obstructive Pulmonary Disease - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Key findings
- Market drivers and constraints
- What factors are driving the market for chronic obstructive pulmonary disease?
- What factors are constraining the market for chronic obstructive pulmonary disease?
- Patient share of select drug classes for mild to moderate COPD in the G7: 2022-2032
- Patient share of select drug classes for severe to very severe COPD in the G7: 2022-2032
- Drug-class specific trends
- Long-acting muscarinic antagonists
- Long-acting beta2 agonist/inhaled corticosteroid fixed-dose combinations
- Long-acting beta2 agonist/long-acting muscarinic antagonist FDCs
- Long-acting beta2 agonist/long-acting muscarinic antagonist/inhaled corticosteroid FDCs
- Long-acting beta 2 agonists
- Short-acting bronchodilators
- Inhaled PDE inhibitors
- IL-13 / IL-4 inhibitors
- IL-5 inhibitors
- IL-33 inhibitors
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Access & Reimbursement Overview
- Methodology
- Appendix
Anupama Joshi, M.S. (Pharm.), Healthcare Research & Data Analyst, Immune and Inflammation. Anupama is an analyst on the Immune and Inflammation team at Clarivate. Her focus is on respiratory diseases, particularly chronic obstructive pulmonary disease. Prior to joining Clarivate, Ms. Joshi was a research scientist in Dr. Reddy’s Laboratories. She obtained her master’s degree in pharmaceutical analysis from the National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali), India.
Navya Vardhan, M.Sc., Epidemiologist, Epidemiology. She obtained her M.Sc. in biostatistics and demography from the International Institute for Population Sciences in Mumbai. She also holds a B.Sc. in mathematics.